top of page

Occam Places Paul Thibodeau as CBO of Hotspot

HotSpot Therapeutics, an Atlas investment that has raised $190M to date, is pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases.

Thibodeau joins HotSpot from Novartis where he held numerous business development positions, most recently leading M&A transactions across all of Novartis’ therapeutic areas, where he was responsible for deal sourcing, evaluation, and execution of acquisitions and divestments. Prior to joining Novartis in 2016, he served as Senior Director of Global Business Development at Teva Cephalon, heading up all out-licensing and discovery deals for its specialty pipeline. Previously, he held numerous business development positions with increasing responsibilities at Sanofi Genzyme across its oncology, transplant and multiple sclerosis franchises.

Thibodeau was a Postdoctoral Research Fellow at the Institut national scientifique et de la recherche médicale (INSERM) in Paris, France. He received his Ph.D. in Cell Biology and Radiobiology from the Université de Sherbrooke in Quebec, Canada, and his B.S. in Biology and Biochemistry from the Université de Moncton in New Brunswick, Canada. He also completed a MBA at the MIT Sloan School of Management.

bottom of page